Janssen Pharmaceutica Nv

Abbvie Inc.

Hillary M Peltier

Hariharan Venkatesan

Mark D Rosen

Lucy Xiumin Zhao

Michael H Rabinowitz

Kyle T Tarantino

Victor K Phuong

Barry Eastman Leonard, Jr

Frances Meredith Hocutt

Marlon D Cowart

David A DeGoey

John R Koenig

Meena V Patel

Michael E Kort

Bo Liu

Derek W Nelson

Tammie K Jinkerson

Marc J Scanio

Andrew Bogdan

Mark A Matulenko

Brian D Wakefield

Barry Eastman Leonard

The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

Benzoimidazoles as prolyl hydroxylase inhibitors

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity. 

Growing community of inventors

San Diego, CA, United States of America

Hillary M Peltier